

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

| | |
|----------------|------------------------------|
| Name of entity | INTEGRAL DIAGNOSTICS LIMITED |
| ABN | 55 130 832 816 |

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

| | |
|---------------------|-----------------|
| Name of Director | Ian Kadish |
| Date of last notice | 1 December 2023 |

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

| | |
|---|--|
| Direct or indirect interest | Direct |
| Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small> | N/A |
| Date of change | 30 November 2023 and 1 December 2023 |
| No. of securities held prior to change | <u>Ordinary Shares</u> 539,441 fully paid ordinary shares <u>Performance Rights (Rights) relating to LTI Plan</u> 184,616 Rights approved by Shareholders 28 Oct 2020 157,371 Rights approved by Shareholders 5 Nov 2021 241,591 Rights approved by Shareholders 4 Nov 2022 <u>248,970</u> Rights approved by Shareholders 29 Nov 2023 832,548 Rights <u>Performance Rights – STI (STI Rights) relating to STI Plan</u> 26,035 STI Rights approved by shareholders 4 Nov 2022 |
| Class | Fully Paid Ordinary Shares |
| Number acquired | 20,000 Ordinary Shares |

Appendix 3Y
Change of Director's Interest Notice

| | |
|--|---|
| Number disposed | Nil |
| Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation | \$1.7525 per Ordinary Share |
| No. of securities held after change | <p><u>Ordinary Shares</u> 559,441 fully paid ordinary shares</p> <p><u>Performance Rights (Rights) relating to LTI Plan</u> 184,616 Rights approved by Shareholders 28 Oct 2020 157,371 Rights approved by Shareholders 5 Nov 2021 241,591 Rights approved by Shareholders 4 Nov 2022 <u>248,970</u> Rights approved by Shareholders 29 Nov 2023 832,548 Rights</p> <p><u>Performance Rights – STI (STI Rights) relating to STI Plan</u> 26,035 STI Rights approved by shareholders 4 Nov 2022</p> |
| Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy- back | Ordinary shares purchased on market |

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

| | |
|--|-----|
| Detail of contract | N/A |
| Nature of interest | N/A |
| Name of registered holder (if issued securities) | N/A |
| Date of change | N/A |
| No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed | N/A |
| Interest acquired | N/A |
| Interest disposed | N/A |
| Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation | N/A |
| Interest after change | N/A |

Part 3 – ⁺Closed period

| | |
|---|-----|
| Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required? | N/A |
| If so, was prior written clearance provided to allow the trade to proceed during this period? | N/A |
| If prior written clearance was provided, on what date was this provided? | N/A |

⁺ See chapter 19 for defined terms.